Skip to content

Development of Population Norms of the Computerized Neuropsychological Assessment for Effectiveness of the Antipsychotic Treatment in Schizophrenia

Development of Population Norms of the Computerized Neuropsychological Assessment for Effectiveness of the Antipsychotic Treatment in Schizophrenia

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00789906
Enrollment
700
Registered
2008-11-13
Start date
2008-07-31
Completion date
Unknown
Last updated
2008-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Keywords

Computerized Neuropsychological Assessment, Development of Population Norms of the Computerized Neuropsychological Assessment

Brief summary

Schizophrenia affects cognition, emotion, and behavior. Neuropsychological assessment enables a better understanding of antipsychotic effectiveness and the brain processes, underlying cognitive functioning in schizophrenia. Neurocognitive deficits in schizophrenia patients appears to explain up to 61% of the variance of functional outcome and is an important predictor of social reintegration (Peuskens et al, 2005) and independent living activitiy (Green et al, 2004). Impaired social functioning within schizophrenia population has been associated with increased health-care costs. Since social and occupational disability may generate the largest indirect costs of the illness, treatment of cognitive deficits has an enormous impact on the cost and disability associated with schizophrenia (McGurk and Mueser, 2004). However, the gap between cognitive science and clinical practice limits the implementation of cognitive assessment in the routine evaluation of schizophrenia patients. Pharmaceutical industry initiated numerous large scale, multisite studies on the impact of novel antipsychotics on cognitive deficits in schizophrenia patients. The aim of this research is to develop population norms of the computerized neuropsychological assessment for effectiveness of the antipsychotic treatment in schizophrenia.

Interventions

None listed

Sponsors

BeerYaakov Mental Health Center
Lead SponsorOTHER_GOV

Study design

Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 89 Years
Healthy volunteers
Yes

Inclusion criteria

* An IQ, which is within normal range.

Exclusion criteria

* Psychiatric co-morbidity. * Physical disability or illness. * A history of severe head injury.

Countries

Israel

Contacts

Primary ContactSemyon Kertzman, MD
research@beerness.health.gov.il972-8-9776136

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026